Can Oseltamivir Cause Stevens-Johnson Syndrome?
Yes, oseltamivir can cause Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), though this is a rare but serious adverse effect explicitly recognized in the FDA drug label. 1
FDA-Recognized Risk
The FDA label for oseltamivir explicitly lists SJS and TEN as serious skin/hypersensitivity reactions in both the contraindications and warnings sections. The drug is contraindicated in patients with known serious hypersensitivity to oseltamivir, and cases of anaphylaxis, toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have been reported in postmarketing surveillance. 1 The label mandates immediate discontinuation of oseltamivir and institution of appropriate treatment if an allergic-like reaction occurs or is suspected 1.
Clinical Evidence
Case reports confirm this association in real-world practice. A documented case involved a 9-year-old girl who developed generalized maculopapular rash the second day after taking oseltamivir, progressing to SJS/TEN with cytotoxic skin lesions and mucous membrane involvement 2. Another case described TEN in a Down syndrome patient following oseltamivir treatment 3.
Critical Diagnostic Consideration
A major clinical pitfall is distinguishing between oseltamivir-induced SJS/TEN and influenza-associated SJS/TEN, as influenza infection itself can trigger these reactions. One case report described a 2-year-old with influenza B who developed SJS while on oseltamivir, highlighting this diagnostic challenge 4. This distinction is crucial because:
- If the drug caused SJS/TEN, oseltamivir must be permanently avoided
- If influenza caused it, the patient may safely receive oseltamivir in the future (as demonstrated in the case where subsequent influenza vaccination was well-tolerated) 4
Immediate Management Algorithm
When SJS/TEN is suspected in a patient taking oseltamivir:
- Stop oseltamivir immediately - this is the single most important intervention 1
- Refer immediately to an SJS/TEN multidisciplinary team 5, 6
- Assess severity using SCORTEN to predict mortality and guide intensity of care 5
- Transfer to a center with SJS/TEN management experience if body surface area involvement >10% or patient has comorbidities 6
- Institute supportive care including wound management, fluid resuscitation, and monitoring for sepsis 5
Relative Risk Context
While oseltamivir can cause SJS/TEN, recent pharmacovigilance data shows antibiotics (particularly sulfamethoxazole), NSAIDs, and anticonvulsants remain the most common culprits overall 7, 8. Carbamazepine, levofloxacin, ibuprofen, and aspirin are among the highest-risk individual drugs 8. Oseltamivir appears less frequently implicated than these agents, but the association is real and documented.
Clinical Bottom Line
Oseltamivir is a recognized cause of SJS/TEN per FDA labeling and case reports. Discontinue immediately if SJS/TEN develops, refer urgently to specialized care, and document the reaction to prevent future exposure. The challenge lies in determining whether oseltamivir or the underlying influenza infection triggered the reaction, which may require specialist evaluation and potentially HLA typing 2.